Comprehensive review of US's clinical trials system needed
An editorial in Nature by Arthur Ammann points out a number of problems with our current clinical trial system:
69 posts
A Tumblr collecting links, commentary, and notes on reproducibility, publication bias, research integrity, and the sociology of science. Originally at metascience.shaunagm.net (2012–2013).
An editorial in Nature by Arthur Ammann points out a number of problems with our current clinical trial system:
This is a little old - I’m going through my bookmarks - but:
From a paper published in 1945 by Vannevar Bush, head of the U.S. Office of Scientific Research and Development (OSRD) during World War II:
The recent announcement that the University of California - the world’s largest public university system - will be embracing open access has been meet with celebration. However, the new policy only encourages faculty to share their work - there are no requirements. Meanwhile, the UC Regents have voted to create a new corporate entity to manage research funding:
From Retraction Watch, a story about a retraction is really a story about Nature’s failure to publish a refutation:
This PLoS One study attempted to look at how pressure to publish might influence the prevalence of positive results. The author, Daniele Fanelli, made an odd choice by using ‘papers per capita by state’ as the measure of pressure to publish. The state seems way too macro a level to look at. I would expect pressure to vary strongly between schools and between departments within schools. There’s no reasoning for this given in the paper - I suspect that it was just simpler to use this measure, already provided by the NSF, then to come up with a method for looking at individual institutions.
This article about Bionimbus, about an effort to efficiently and securely share cancer genomics data, mentions the Open Science Data Cloud. The OSDC is a platform for sharing large datasets, and although their current set of projects, including Bionimbus, are mostly genomics-focused, they seem to be open to datasets of all types.
A colleague referenced this 2010 paper which measures proportion of positive results by scientific discipline.
A quick note on an interesting point raised by Roger Peng:
A paper and associated web-based tool have been proposed to detect publication bias and p-hacking in the literature. From the paper:
I spent three years working in fMRI labs. To this day it’s not clear to me if the field has exceptionally ambiguous standards, or if it’s only one of many scientific subfields based around new technology struggling to define good practice. Whether it’s got company or not, neuroimaging certainly has issues.
There’s an op ed in the New York Times about how a coding error in an economics article may have had profoundly negative influence on economic policy:
There’s a new article out in Nature Reviews Neuroscience about the failure of scientific studies in general (and neuroscience and fMRI studies in particular) to adequately power their studies. The NRN paper isn’t open access, but you can email the authors for a pre-print. There’s a good write-up at National Geographic.
An article in the Washington Post details an alleged case of Fraud which led to an as-yet-uncorrected Nature paper and a suicide:
An opinion article from Iain Chalmers (of the very well regarded though not fully open access Cochrane Collaboration) and Paul Glasziou (of the Center for Evidence-based Medicine) discusses the high potential for waste in much research.
The Obama administration has announced that all research funded by federal agencies (with R&D budgets greater than $100 million) should be made open access within one year of publication:
An interesting article from Accident Analysis and Prevention from 2004 goes over three case studies where Null Hypothesis Significance Testing may have cost lives.
On the PLoS blog, an article from Jack Andraka, winner of the 2012 Intel Science prize for the invention of a dip stick test for pancreatic cancer, on trying to reach behind paywalls as a 14 year old:
Found this interesting paper from a couple years ago: Detecting and Correcting the Lies that Data Tellby F Schmidt.
This post at the Scholarly Kitchen touches on a number of arguments against mandatory CC-BY licensing. They’re all worth talking about, although none seem worth keeping science behind closed doors.
A new PLoS one paper looked at the outcome of 1054 trials submitted to the ethics committee of a major Spanish hospital from 1997-2004. This flowchart captures the basic results:
It’s been my experience that I wildly disagree with some of the fundamental values of the folks at Scholarly Kitchen, but I get a lot out of their posts and arguments. Their most recent post on a possible scandal at Pub Med Central is a case in point:
A relevant follow up to the last post. Science critic Ben Goldacre has a new project: a petition to get all trials registered and to enforce reporting deadlines.
An article in BMJ explores how well registered trials adhere to reporting deadlines.
A new PLoS Medicine report investigated how pharmaceutical promotions and advertising influence prescriptions:
Back in November, Perspectives on Psychological Science put out a special issue on replicability. I’ll be attempting to summarize each of the articles in that issue for this tumblr. See this post for links to all article summaries, or use this tag to browse.
A brief comment points out a major flaw in a published study, in part by using simulations:
A friend forwarded me this paper, “Empirical estimates suggest most published medical research is true”, perhaps in an attempt to challenge my cynicism. I like to believe I am open to being challenged, and I do recognize that purposefully cataloging problems with research leaves me biased. But I don’t think this paper is the best counterpoint.
A post at Retraction Watch summarizes the situation:
A recent paper did an analysis of breast cancer studies published over the last 16 years. They evaluated 164 trials and looked at whether results re: the drug’s toxicity or overall survival rate was reported prominently in the abstract, within the article, or at all. They looked at who funded the work, the impact factor of the journal the work was published in, and most interestingly, whether the trial found positive or negative results.
Back in November, Perspectives on Psychological Science put outa special issue on replicability. I’ll be attempting to summarize each of the articles in that issue for this tumblr. See this post for links to all article summaries, or use this tag to browse.
Perspectives on Psychological Science recently came out with a special issue on replicability in psychology research and its implications for the reliability and health of the field as a whole. They cite as motivation the last two years, which have been filled with fraud, admissions of questionable research practices, a published paper in a major paper claiming evidence of ESP, reports that researchers cannot or will not share data or disclose the full extent of their analyses, and the failure to replicate several major findings in the field.
Back in November, Perspectives on Psychological Science put out a special issue on replicability. I’ll be attempting to summarize each of the articles in that issue for this tumblr. See this post for links to all article summaries, or use this tag to browse.
Science Fraud faces legal threats
This review of Diederik Stapel’s autobiography quotes this interesting passage:
I found this 2004 article through the footnotes of Nate Silver’s book. Here are the highlights (but I recommend reading it all the way through.)
This article raises, for me at least, the interesting question of whether the large amount of research that remains uncited in medical/scientific literature is a good thing, a bad thing, or a neutral thing. I did a little more reading, and found some other posts on the topic.
Scientists Propose Central Database for Disclosing Conflicts of Interest
This article (warning: pdf) talks in detail about how the psychology community frequently fails to account for the great diversity of cultures in our world.
From this post:
Article Level Metadata
This article focuses on making study results available to patients who are providing the medical data. But it touches on more general themes - on the right of patients not just to control their own data but to access the results of research into their illnesses, and to be empowered to do some of the research themselves.
Stapel Report
I normally do not post about sexism, racism, and other forms of bigotry in the scientific community here. While I obviously think they exist and am against them, it is ambiguous how these “isms” impact/bias the scientific literature. (I am sure they do. But perhaps in a less concrete way than, say, the file-drawer phenomenon, or clear misuse of statistics.)
From the copy on their website:
Retractions stigmatize scientific fields, study finds
Quoting my own write up:
Vaughn Bell of Mind Hacks interviews researchers about the problems with fMRI:
Dorothy Bishop critiques a 2003 neuroimaging paper:
From the article:
“A Systematic Review and Meta-Analysis of Survey Data”
(Lots of other interesting non-dismal-sciencey results here.)
A pair of articles in Infection and Immunity. In addition to summarizing problems, they offer the following reforms (all greatly abridged in the excerpts below):
As described in this Nature article:
From the article:
Reproducibility Project
Why Most Published Research Findings Are False
Surely You're Joking... : The Oil Drop Experiment
Contradicted and Initially Stronger Effects in Highly Cited Clinical Research
402 Citations Questioning the Indiscriminate Use of Null Hypothesis Significance Tests in Observational Studies
The decline effect and the scientific method
Walking Fast and Slow
We Must Stop The Avalanche of Low Quality Research
If you want reproducible science, the software needs to be open source.
Solutions: Dryad Data Repository
Journal Disavows Study Touted By Abortion Foes
How Corporations Corrupt Science at the Public's Expense